Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The spike glycoprotein (S protein) is a large, trimeric, class I fusion protein found on the surface of SARS-CoV-2, including its Omicron XBB.1.5 variant. It mediates viral entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor and facilitating membrane fusion. The S protein is also the primary target for neutralizing antibodies and vaccines. Omicron XBB.1.5 variant has specific mutations that enhance immune evasion.
The spike glycoprotein mediates viral attachment to host cells via ACE2 binding followed by triggering virus-cell membrane fusion through irreversible structural rearrangements post-cleavage and activation. Neutralizing antibodies block ACE2 binding and/or prevent conformational changes necessary for membrane fusion.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spike Glycoprotein of SARS-CoV-2 (Omicron XBB.1.5) (S protein).